Multivalent streptococcal vaccine compositions and methods for use
AssigneeThe University of Tennessee Research Corporation
InventorsMark A. Reddish, Mary ChaoHong Hu, Michael A. Walls, James B. Dale
Life of this patent
Estimating the term…
Abstract
Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nucleic acids encoding such hybrid polypeptides. The hybrid polypeptide formulations may be used, for example, in methods for treating or preventing a microbial infection and eliciting a protective immune response having broadly protective opsonic antibodies in the absence of tissue cross-reactive antibodies.
Claims70
A hybrid polypeptide, comprising at least six different linked immunogenic peptides, wherein each peptide comprises an amino-terminal portion of a streptococcal M protein of at least 30 amino acids, and wherein the polypeptide has an amino-terminal peptide that is reiterated as a carboxy-terminal peptide and the polypeptide is capable of eliciting an immune response against more than one antigen of group A streptococci comprising at least M5, M6, M14, M19, M24, and M29.
A hybrid polypeptide, comprising at least seven different linked immunogenic peptides, wherein each peptide comprises an amino-terminal portion of a streptococcal M protein of at least 35 amino acids, and wherein the polypeptide has an amino-terminal peptide that is reiterated as a carboxy-terminal peptide and the polypeptide is capable of eliciting an immune response against more than one antigen of group A streptococci comprising at least M2, M11, M22, M33, M43, M59, and M94.
A hybrid polypeptide, comprising at least seven different linked immunogenic peptides, wherein each peptide comprises an amino-terminal portion of a streptococcal M protein of at least 40 amino acids, and wherein the polypeptide has an amino-terminal peptide that is reiterated as a carboxy-terminal peptide and the polypeptide is capable of eliciting an immune response against more than one antigen of group A streptococci comprising at least M75, M76, M77, M89, M92, M101, and M114.
A hybrid polypeptide, comprising at least seven different immunogenic peptides linked in tandem, wherein each peptide comprises an amino-terminal portion of a streptococcal M protein of at least 50 amino acids and, and wherein the polypeptide has an amino-terminal peptide that is reiterated as a carboxy-terminal peptide and the polypeptide is capable of eliciting an immune response against more than one antigen of group A streptococci comprising at least Spa, M1.0, M1.2, M3, M12, M18, and M28.
A hybrid polypeptide comprising the amino acid sequence of SEQ ID NOS:2, 4, 6, or 8.
A nucleic acid molecule comprising a sequence encoding a hybrid polypeptide of SEQ ID NOS:2, 4, 6, or 8.
A nucleic acid expression construct comprising an expression control sequence operably linked to a polynucleotide encoding a hybrid polypeptide of SEQ ID NOS:2, 4, 6, or 8.
A method of producing a hybrid polypeptide, comprising culturing a host cell containing a nucleic acid expression vector comprising at least one expression control sequence operably linked to a nucleic acid molecule encoding a hybrid polypeptide of SEQ ID NOS:2, 4, 6, or 8, under conditions and for a time sufficient for expression of the polypeptide.
Dependencies are inferred from the claim text.